637 related articles for article (PubMed ID: 31733655)
1. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
3. LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons.
Henderson MX; Changolkar L; Trojanowski JQ; Lee VMY
J Parkinsons Dis; 2021; 11(3):1187-1196. PubMed ID: 33720852
[TBL] [Abstract][Full Text] [Related]
4. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
Lubben N; Brynildsen JK; Webb CM; Li HL; Leyns CEG; Changolkar L; Zhang B; Meymand ES; O'Reilly M; Madaj Z; DeWeerd D; Fell MJ; Lee VMY; Bassett DS; Henderson MX
Transl Neurodegener; 2024 Mar; 13(1):13. PubMed ID: 38438877
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of LRRK2 in tauopathies.
Herbst S; Lewis PA; Morris HR
Clin Sci (Lond); 2022 Jul; 136(13):1071-1079. PubMed ID: 35815712
[TBL] [Abstract][Full Text] [Related]
6. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.
Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA
Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873
[TBL] [Abstract][Full Text] [Related]
7. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.
Ling H; Kara E; Bandopadhyay R; Hardy J; Holton J; Xiromerisiou G; Lees A; Houlden H; Revesz T
Neurobiol Aging; 2013 Dec; 34(12):2889.e5-9. PubMed ID: 23664753
[TBL] [Abstract][Full Text] [Related]
8. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
Henderson MX; Peng C; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
[TBL] [Abstract][Full Text] [Related]
10. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
[TBL] [Abstract][Full Text] [Related]
11. Pathological Functions of LRRK2 in Parkinson's Disease.
Jeong GR; Lee BD
Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy.
Lee K; Nguyen KD; Sun C; Liu M; Zafar F; Saetern J; Flierl A; Tetrud JW; Langston JW; Dickson D; Schüle B
J Parkinsons Dis; 2018; 8(1):93-100. PubMed ID: 29480226
[TBL] [Abstract][Full Text] [Related]
14. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
[TBL] [Abstract][Full Text] [Related]
15.
Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A;
Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166
[TBL] [Abstract][Full Text] [Related]
16. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
[TBL] [Abstract][Full Text] [Related]
17. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.
Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R
Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers.
Aasly JO; Shi M; Sossi V; Stewart T; Johansen KK; Wszolek ZK; Uitti RJ; Hasegawa K; Yokoyama T; Zabetian CP; Kim HM; Leverenz JB; Ginghina C; Armaly J; Edwards KL; Snapinn KW; Stoessl AJ; Zhang J
Neurology; 2012 Jan; 78(1):55-61. PubMed ID: 22170881
[TBL] [Abstract][Full Text] [Related]
19. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain.
Nguyen APT; Daniel G; Valdés P; Islam MS; Schneider BL; Moore DJ
Hum Mol Genet; 2018 Jan; 27(1):120-134. PubMed ID: 29088368
[TBL] [Abstract][Full Text] [Related]
20. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
